FDAはメルスの新薬 ビゼニリを承認 高度な すい臓と肺のがんの治療 The FDA approved Merus' new cancer drug, Bizengri, for treating advanced pancreatic and lung cancers.

米国食品医薬品局は、メラヌスの新薬,ビゼングリを, すい臓と肺の高性能NRG1陽性のがんの治療について,迅速に承認した. The U.S. FDA has granted accelerated approval to Merus' new drug, Bizengri, for treating advanced NRG1-positive cancers in the pancreas and lungs. 住血吸虫腫と非小細胞肺がんの承認を受け,同薬の承認は,ENRGY試験の予備データに基づいており,その有効性を確認するための研究が継続している. Approved for pancreatic adenocarcinoma and non-small cell lung cancer, the drug's approval is based on preliminary data from the eNRGy trial, with ongoing studies to confirm its efficacy. Merus''s Biclonics技術のFDAが初めて承認された. This marks the first FDA approval for Merus' Biclonics technology.